alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 4,701–4,725 of 27,146 studies marked Peer-reviewed (page 189 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

A systematic literature review of automatic Alzheimer's disease detection from speech and language

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of the American Medical Informatics Association : JAMIA 2020-11-01

The systematic literature review supported the argument that language and speech could successfully be used to detect dementia automatically. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The effect of digital reminiscence therapy on people with dementia: a pilot randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 60 out of 100. BMC geriatrics 2020-05-06

Digital RT proved an innovative approach to manage PWD and will thus help PWD achieve a better mood and have more opportunities to engage in social interactions. 3 key findings →

Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Executive function and falls in older adults: new findings from a five-year prospective study link fall risk to cognition

✓ Peer-reviewed alzhub usefulness score 60 out of 100. PloS one 2012-06-29

Survival analyses indicated that subjects with the lowest EF scores were more likely to fall sooner and more likely to experience multiple falls during the 66 months of follow-up (p Conclusions/significance These findings demonstrate that among community-living older adults, the risk of future falls was predicted by performance on EF and attention tests conducted 5 years earlier. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01

In the last decade, the association between diet and cognitive function or dementia has been largely investigated. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Diabetes research and clinical practice 2000-12-01

Routine screening of cognition in older subjects with diabetes is recommended. 3 key findings →

Design: case-control study Participants: 396 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The striatum is an early, accurate indicator of amyloid burden using [11C]PiB in Down syndrome: Comparison of two radiotracers

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-04-01

Among adults with Down syndrome, the striatum consistently accumulates amyloid earlier than the cortex when measured with PiB. 2 key findings →

Design: longitudinal study Participants: 175 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Trials 2016-07-29

Aβ40 levels changed less for the simvastatin group (not statistically significant). 4 key findings →

Design: cohort study Participants: 21 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Small vessel disease: mechanisms and clinical implications

✓ Peer-reviewed alzhub usefulness score 60 out of 100. The Lancet. Neurology 2019-05-13

Small vessel disease is a disorder of cerebral microvessels that causes white matter hyperintensities and several other common abnormalities (eg, recent small subcortical infarcts and lacunes) seen on brain imaging. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Nature 2018-05-09

In Lewy body diseases-including Parkinson's disease, without or with dementia, dementia with Lewy bodies, and Alzheimer's disease with Lewy body co-pathology 1 -α-synuclein (α-Syn) aggregates in neurons as Lewy bodies and Lewy neurites 2 . 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Nature medicine 2018-02-05

An intronic GGGGCC repeat expansion in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but the pathogenic mechanism of this repeat remains unclear. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropathological changes in essential tremor: 33 cases compared with 21 controls

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Brain : a journal of neurology 2007-11-19

Despite its being one of the most commonly observed neurological disorders, neuropathological studies of essential tremor (ET) are rare. 2 key findings →

Design: case-control study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Brain : a journal of neurology 2009-01-21

Mutations in the progranulin gene (GRN) are an important cause of frontotemporal lobar degeneration (FTLD) with ubiquitin and TAR DNA-binding protein 43 (TDP43)-positive pathology. 3 key findings →

Participants: 219 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review) [RETIRED]. Report of the Quality Standards Subcommittee of the American Academy of Neurology

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2001-05-01

There were insufficient data to make any recommendations regarding cognitive screening of asymptomatic individuals. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Archives of neurology 2006-04-01

Interferon-gamma-inducible protein 10 is specifically increased in MCI and seems to decrease with the progression of AD, whereas MCP-1 and IL-8 are up-regulated also in late stages of the disease, suggesting a role in phases in which neurodegeneration is prevalent. 3 key findings →

Design: longitudinal study Participants: 36 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed